SCHEMBL3092901

SCHEMBL3092901

NC(=O)C1(Cc2cc(CCNC(=O)CC(F)(F)F)ccc2Cl)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.39
REN P00797 1/20 0.39
CYP3A4 P08684 1/20 0.39
TRPV1 Q8NER1 1/20 0.38
PYGL P06737 1/20 0.36
CA1 P00915 4/20 0.35
CA2 P00918 4/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
DPP4 P27487 1/20 0.35
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
LMNA P02545 1/20 0.34
HSD17B2 P37059 1/20 0.34
GLA P06280 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
MEN1 O00255 1/20 0.33
HPGD P15428 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636015 0.89 HSD11B1 (0.40) HSD11B1RENCYP3A4TRPV1CA1
SCHEMBL2635461 0.83 KDM4E (0.46) HSD11B1ALDH1A1LMNAHPGDSMN1; SMN2
SCHEMBL3088348 0.81 ADRA2A (0.40) HSD11B1RENCYP3A4PYGLALDH1A1
SCHEMBL3079767 0.81 TRPV1 (0.44) RENCYP3A4TRPV1PYGLCA1
SCHEMBL3086063 0.79 HTR1A (0.40) HSD11B1RENCYP3A4PYGLMEN1
SCHEMBL2635811 0.78 REN (0.37) HSD11B1RENMEN1KMT2A
SCHEMBL2635860 0.78 KDM4E (0.42) HSD11B1RENMEN1KMT2A
SCHEMBL2635483 0.77 KMT2A (0.40) HSD11B1RENCYP3A4TRPV1PYGL
SCHEMBL3085141 0.76 REN (0.42) RENCYP3A4TRPV1PYGLCA1
SCHEMBL3092898 0.75 EPHX2 (0.43) RENCYP3A4GAADPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US claimed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US claimed
EP-1893578-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-05 EP claimed
WO-2006129237-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-07 WO claimed
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES BEZENCON OLIVIER 2010-12-23 US disclosed
US-7799805-B2 Piperidine carboxylic acid amide derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-09-21 US disclosed
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives ACTELION PHARMACEUTICALS LTD (CH) 2008-09-04 US disclosed
EP-1893578-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-03-05 EP disclosed
WO-2006129237-A2 NOVEL PIPERIDINE CARBOXYLIC ACID AMIDE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214598-A1 Novel Piperidine Carboxylic Acid Amide Derivatives REN, ACE, AGTR2 HSD11B1 3856/4885REN 1/4885CYP3A4 709/4885
US-20100324052-A1 NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES REN, ACE, AGTR2 HSD11B1 3674/4885REN 1/4885CYP3A4 676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.